Therapeutic Research

Abstract

Aim：To clarify the factors that contribute to the change in HbA1c after increasing the dose of Luseogliflozin（LSF）from 2.5 to 5 mg. 　　Method：We retrospectively analyzed 109 patients with type 2 diabetes mellitus who increased the dose of LSF from 2.5 to 5 mg and continued taking it for more than 3 months. HbA1c, BMI, and metabolic factors were extracted 3 months before, at the time of, and 3 months after increasing LSF from 2.5 to 5 mg. Univariate analysis was performed on the relationship between ⊿HbA1c after increasing the dose and each factor, and factors contributing to ⊿HbA1c（after increasing the dose）were examined using multiple regression analysis. 　　Results：After increasing the LSF dose from 2.5 to 5 mg, ⊿HbA1c was correlated with HbA1c at the time of increase the dose and ⊿HbA1c before increasing the dose. Multiple regression analysis revealed that the independent variables of the dependent variable ⊿HbA1c（after increasing the dose）were HbA1c at the time of increasing the dose, ⊿HbA1c before increasing the dose, and ⊿BMI before increasing the dose. 　　Conclusion：Improvement in HbA1c by increasing the dose of LSF from 2.5 to 5 mg can be expected in 1）cases with high HbA1c, 2）cases with increasing tendency in HbA1c, and 3）cases with decreasing tendency in BMI.